BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, December 15, 2024
See today's BioWorld Asia
Home
» Diatos Licenses European Rights To Cancer Drug From Medarex
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Diatos Licenses European Rights To Cancer Drug From Medarex
April 30, 2003
By
James Etheridge
No Comments
PARIS - Diatos SA and Medarex Inc. signed a licensing agreement giving Diatos exclusive European rights to develop and commercialize a potential new cancer treatment. (BioWorld International)
BioWorld Asia
